Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients
暂无分享,去创建一个
Jin-Hee Ahn | Min-Woo Jo | H. Kim | Jin-Hee Ahn | M. Jo | Seon Ha Kim | Hwa-Jung Kim | Seon-Ha Kim | J. Ahn | Seon Ha Kim
[1] John Brazier,et al. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? , 2009, Health and quality of life outcomes.
[2] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .
[3] D. Feeny,et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.
[4] M. Versteegh,et al. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[5] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[6] Aki Tsuchiya,et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures , 2010, The European Journal of Health Economics.
[7] R. Brooks. EuroQol: the current state of play. , 1996, Health policy.
[8] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[9] M. Boyle,et al. Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.
[10] M. van der Pol,et al. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[11] H. Kim,et al. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea , 2012, Quality of Life Research.
[12] M. Jo,et al. Validity and reliability of the EQ-5D for cancer patients in Korea , 2012, Supportive Care in Cancer.
[13] Andrew Briggs,et al. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences , 2010, The European Journal of Health Economics.
[14] Hye-young Kang,et al. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients , 2012, Quality of Life Research.
[15] Nick Kontodimopoulos,et al. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[17] Benjamin M Craig,et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] Frank de Charro,et al. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective , 2003, Springer Netherlands.
[19] Paul Kind,et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] R. Deyo,et al. Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life , 1989, Medical care.
[21] Desmond Curran,et al. EORTC QLQ-C30 Scoring Manual (2nd edition) , 1999 .
[22] Donna Rowen,et al. Mapping onto Eq-5 D for patients in poor health , 2010, Health and quality of life outcomes.
[23] D. Heo,et al. Validation of the Korean version of the EORTC QLQ-C30 , 2004, Quality of Life Research.